Literature DB >> 7960137

Synthesis and some immunologic properties of an O-acetyl pectin [poly(1-->4)-alpha-D-GalpA]-protein conjugate as a vaccine for typhoid fever.

S C Szu1, S Bystricky, M Hinojosa-Ahumada, W Egan, J B Robbins.   

Abstract

Pectin, a plant polysaccharide, is mostly a linear homopolymer of poly(1-->4)-alpha-D-GalpA with < 5% neutral sugars: its molecular size has a broad distribution around 400 kDa, and the degree of esterification is < 5%. The structure of the capsular polysaccharide of Salmonella typhi (Vi) differs from pectin in that it is N acetylated at C-2 and O acetylated at C-3, and has a molecular size of approximately 2 x 10(3) kDa. There is no serological cross-reaction between pectin and Vi. Pectin, when O acetylated at C-2 and C-3, is antigenically identical to Vi in double immunodiffusion. Unlike Vi, O-acetylated pectin (OAcPec) is not immunogenic in mice, probably because of its comparatively low molecular weight. After storage at 3 to 8 degrees C for 3 months, there was no change in the O-acetyl content or the M(r) of OAcPec. At 60 degrees C, the M(r) of OAcPec declined more rapidly than that of Vi. OAcPec conjugated to tetanus toxoid elicited Vi antibodies in mice, and reinjection elicited a booster response. The levels of Vi antibodies elicited by OAcPec-tetanus toxoid conjugates were lower than those elicited by Vi conjugates, but these differences were not statistically significant. OAcPec has some advantages because it can be measured by standardized colorimetric assays and because it forms more soluble conjugates with proteins than does Vi. One disadvantage is that its glycosidic bond is not as stable as that of Vi. The use of a plant polysaccharide, pectin, as an immunogen for prevention of a systemic infection caused by a capsulated pathogen (S. typhi) provides a novel approach to improve the preparation and immunogenicity of polysaccharide-based vaccines.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7960137      PMCID: PMC303300          DOI: 10.1128/iai.62.12.5545-5549.1994

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.609


  22 in total

1.  Immunochemistry of the pneumococcal types II. V. and VI. I. The relation of Type VI to Type II and other correlations between chemical constitution and precipitation in antisera to type VI.

Authors:  M HEIDELBERGER; P A REBERS
Journal:  J Bacteriol       Date:  1960-08       Impact factor: 3.490

2.  Application of optical properties of the Vi capsular polysaccharide for quantitation of the Vi antigen in vaccines for typhoid fever.

Authors:  A L Stone; S C Szu
Journal:  J Clin Microbiol       Date:  1988-04       Impact factor: 5.948

3.  Physicochemical and biological properties of sonically treated Vi antigen.

Authors:  D G Martin; F G Jarvis; K C Milner
Journal:  J Bacteriol       Date:  1967-11       Impact factor: 3.490

4.  Protective activity of Vi capsular polysaccharide vaccine against typhoid fever.

Authors:  K P Klugman; I T Gilbertson; H J Koornhof; J B Robbins; R Schneerson; D Schulz; M Cadoz; J Armand
Journal:  Lancet       Date:  1987-11-21       Impact factor: 79.321

5.  Comparative immunogenicities of Vi polysaccharide-protein conjugates composed of cholera toxin or its B subunit as a carrier bound to high- or lower-molecular-weight Vi.

Authors:  S C Szu; X R Li; R Schneerson; J H Vickers; D Bryla; J B Robbins
Journal:  Infect Immun       Date:  1989-12       Impact factor: 3.441

6.  Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report.

Authors:  I L Acharya; C U Lowe; R Thapa; V L Gurubacharya; M B Shrestha; M Cadoz; D Schulz; J Armand; D A Bryla; B Trollfors
Journal:  N Engl J Med       Date:  1987-10-29       Impact factor: 91.245

7.  Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals.

Authors:  S C Szu; A L Stone; J D Robbins; R Schneerson; J B Robbins
Journal:  J Exp Med       Date:  1987-11-01       Impact factor: 14.307

8.  Immunochemical properties of Vi antigen from Salmonella typhi Ty2: presence of two antigenic determinants.

Authors:  B Szewczyk; A Taylor
Journal:  Infect Immun       Date:  1980-08       Impact factor: 3.441

9.  Measurement of protein using bicinchoninic acid.

Authors:  P K Smith; R I Krohn; G T Hermanson; A K Mallia; F H Gartner; M D Provenzano; E K Fujimoto; N M Goeke; B J Olson; D C Klenk
Journal:  Anal Biochem       Date:  1985-10       Impact factor: 3.365

Review 10.  Reexamination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella typhi.

Authors:  J D Robbins; J B Robbins
Journal:  J Infect Dis       Date:  1984-09       Impact factor: 5.226

View more
  9 in total

1.  Suppression of agglomeration of ciprofloxacin-loaded human serum albumin nanoparticles.

Authors:  P Vijayaraj Kumar; Narendr K Jain
Journal:  AAPS PharmSciTech       Date:  2007-03-02       Impact factor: 3.246

2.  Phase I clinical trial of O-acetylated pectin conjugate, a plant polysaccharide based typhoid vaccine.

Authors:  Shousun C Szu; Kimi F-Y Lin; Steven Hunt; Chiayung Chu; Nguyen Duc Thinh
Journal:  Vaccine       Date:  2014-03-21       Impact factor: 3.641

3.  Physical and chemical characterization and immunologic properties of Salmonella enterica serovar typhi capsular polysaccharide-diphtheria toxoid conjugates.

Authors:  Changfa Cui; Rodney Carbis; So Jung An; Hyun Jang; Cecil Czerkinsky; Shousun C Szu; John D Clemens
Journal:  Clin Vaccine Immunol       Date:  2009-11-04

4.  Synthesis and immunological properties of Vi and di-O-acetyl pectin protein conjugates with adipic acid dihydrazide as the linker.

Authors:  Z Kossaczka; S Bystricky; D A Bryla; J Shiloach; J B Robbins; S C Szu
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

5.  Interplay of Carbohydrate and Carrier in Antibacterial Glycoconjugate Vaccines.

Authors:  Tyler D Moeller; Kevin B Weyant; Matthew P DeLisa
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

6.  Construction and characterization of a Pseudomonas aeruginosa mucoid exopolysaccharide-alginate conjugate vaccine.

Authors:  Christian Theilacker; Fadie T Coleman; Simone Mueschenborn; Nicolas Llosa; Martha Grout; Gerald B Pier
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

7.  Development of a synthetic Vi polysaccharide vaccine for typhoid fever.

Authors:  Yawei Ni; Michael J Springer; Jianhua Guo; Isaac Finger-Baker; James P Wilson; Ronald R Cobb; Debra Turner; Ian Tizard
Journal:  Vaccine       Date:  2017-11-14       Impact factor: 3.641

8.  The influence of conjugation variables on the design and immunogenicity of a glycoconjugate vaccine against Salmonella Typhi.

Authors:  M Arcuri; R Di Benedetto; A F Cunningham; A Saul; C A MacLennan; F Micoli
Journal:  PLoS One       Date:  2017-12-29       Impact factor: 3.240

9.  Short Vi-polysaccharide abrogates T-independent immune response and hyporesponsiveness elicited by long Vi-CRM197 conjugate vaccine.

Authors:  Francesca Micoli; Stefania P Bjarnarson; Melissa Arcuri; Audur Anna Aradottir Pind; Gudbjorg J Magnusdottir; Francesca Necchi; Roberta Di Benedetto; Martina Carducci; Fabiola Schiavo; Carlo Giannelli; Ivan Pisoni; Laura B Martin; Giuseppe Del Giudice; Calman A MacLennan; Rino Rappuoli; Ingileif Jonsdottir; Allan Saul
Journal:  Proc Natl Acad Sci U S A       Date:  2020-09-08       Impact factor: 11.205

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.